Research Published in JSES Indicates that the Catalyst™ CSR Total Shoulder System Outperforms Traditional Stemmed Implants

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has announced the publication of a new study in the Journal of Shoulder and Elbow Surgery that shows positive clinical outcomes using the Catalyst™ CSR total shoulder system, compared to standard stemmed TSAs.

The study, Stemless Total Shoulder Arthroplasty Using a Novel Multiplanar Osteotomy and Elliptical Humeral Head Results in Both Improved Early Range of Motion and Radiographic Center of Rotation Compared to Standard Total Shoulder Arthroplasty (Budge, Orvets), tested and compared early postoperative range of motion (ROM) and restoration of radiographic center of rotation (COR), using the Catalyst anatomic shoulder system and standard stemmed TSAs.

The results demonstrate that patients who received the Catalyst anatomic shoulder replacement achieved better ROM at 6 and 12 weeks, and improved restoration of the radiographic COR when compared to patients who received a standard stemmed TSA with a spherical humeral head.

“The Catalyst CSR anatomic shoulder system uses a multiplanar osteotomy that allows for superior precision and accuracy in shoulder replacement, while preserving more of the patient’s native bone,” said Matthew Budge, M.D., orthopedic surgeon, Kaiser Permanente. “This novel approach leverages both reproduction of the patient’s native humeral head height and offset with an ellipsoid anatomic head. Together, these attributes contributed to a faster recovery time compared to standard stemmed TSA.”

This study was a retrospective review of 50 consecutive primary patients by a single surgeon. Data was collected at 6 weeks, 12 weeks, 6 months, and 12 months postoperative on patients who received 25 stemmed implants from Depuy, Stryker (Wright Medical), Lima & Zimmer Biomet and 25 Catalyst anatomic implants.

95% of patients in the Catalyst group had a change in COR <3mm, compared to only 60% in the stemmed group, indicating that the multiplanar osteotomy and ellipsoid anatomic head result in more consistent reproduction of the humeral head anatomy, supporting better ROM.

“Faster recoveries can be attributed to a combination of several factors working in unison,” said Carl O’Connell, CEO and president of Catalyst. “A more anatomically shaped, ellipsoid humeral head design better mimics the patient’s natural anatomy. Our precision multiplanar osteotomy instrumentation removes a minimal amount of bone and consistently allows for better restoration of the native humeral joint line. And patented, oblique glenoid instruments allow for the glenoid to be prepared with less muscle retraction than a traditional perpendicular approach.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”